Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.35
Bid: 3.30
Ask: 3.40
Change: 0.15 (4.62%)
Spread: 0.10 (3.03%)
Open: 3.25
High: 3.40
Low: 3.40
Prev. Close: 3.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line

Wed, 27th Mar 2024 16:13

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Spectra Systems Corp - Providence, Rhode Island-based authentication technology provider - Reports revenue in 2023 edged up to USD20.2 million from USD19.6 million the year prior. Net income was USD6.0 million, slightly lower than USD6.1 million last time, with diluted earnings per share of 0.13 pence compared to 0.12p. Pays annual dividend of USD0.116 per share, up from USD0.115. Says cash position "remains strong", with cash generation driven by sensor development milestones and prepayments, record sales of covert materials to a central bank, and strong optical materials sales. Believes "that the company is on track to achieve record earnings in 2024."

----------

Infrastructure India PLC - infrastructure fund investing directly into assets in India - Says pretax loss in the six months to September 30 halves to GBP31.6 million from GBP62.2 million the year prior. Basic and diluted loss per share totals 4.77 pence, compared to 5.72p. Says value of investments was GBP99.6 million as at September 30, down from GBP194.1 million the year before.

----------

Metals Exploration PLC - Philippines-focused gold producer - Makes last payment due to the lenders under the mezzanine debt facilities on Monday on the basis of the lower interest rate of 7%, as opposed to 15%, which the company believes should apply under such facilities. Says amount outstanding on the group's senior facility as at Monday stands at USD2,629. Metals Exploration says it has agreed the 7% rate with the majority mezzanine lender, MTL Luxembourg SA. But explains it has been unable to reach agreement as yet, with the minority 29% mezzanine debt lenders, Runruno Holdings Ltd and D & A Holdings Ltd. RHL Group advisers have stated their belief that the higher 15% rate is applicable, which potentially amounts to an additional USD1.9 million owed. But Metals exploration disputes this. Discussions continue. Intends to apply future free cash generated from operations to fund ongoing growth opportunities based on MTL's proven operating track record in the Philippines.

----------

Allergy Therapeutics PLC - Sussex, England-based biotechnology company - Extends cash runway until the first quarter of 2025 following talks with major shareholders SkyGem Acquisition Ltd and Southern Fox Investments Ltd. Lenders agree that a further GBP15 million from the existing GBP40 million amended loan facility, announced on December 27, may be drawn down from the second quarter of 2024. Further, will issue warrants to the lenders following each drawdown under the amended loan facility, entitling the holders to subscribe for new shares at a price of 4 pence each. The entitlement to warrants will be 25 warrants for each GBP1 drawn down under the amended loan facility with a maximum of 1.00 billion warrants. The warrants will be exercisable in whole or in part from July 1 until January 15, 2027. Further, reports pretax loss in the six months to December 31 widens to GBP14.9 million from GBP8.2 million the year prior. Diluted loss per share totals 0.58p compared to LPS of 1.29p. Revenue falls to GBP33.6 million from GBP39.9 million. Explains the decrease in revenue is due to previously reported manufacturing capacity that needed to be allocated to investigational medicinal product batches for use in clinical trials and the ongoing programme of continuous improvement across the supply chain and quality systems paving the way for increased capacity. Demand for the company's products continues to be robust.

----------

Quartix Technologies PLC - Newtown, Wales-based vehicle tracking system provider - Issues trading statement ahead of Wednesday's annual general meeting. Says trading for the first two months of 2024 has been consistent with meeting market expectations for the year. Notes new unit subscriptions for the first quarter of 2024 are expected to be around 10% higher annually. Growth in new subscriptions continues to be led by France and Continental Europe. Further, advises Chief Financial Officer Emily Rees resigns to pursue opportunities outside the company.

----------

Microsaic Systems PLC - Surrey-based developer of real-time mass spectrometers - Reports that having passed quality control specifications, shipments of existing MicroTox reagent stock have begun to meet the demand from clients that are operating Modern Water instruments currently in service. Says stock levels are sufficient to meet this demand until restarted production output from the York facility passes testing and quality control for shipping, as scheduled for April. Further, agrees terms with GX Group, based in Usk Wales, for the continued manufacturing and further development of continuous toxicity monitoring instruments previously sold by the Modern Water business. Acting Executive Chair Bob Moore says: "The combination of Modern Water and Microsaic technologies is underway as planned."

----------

Kingfisher PLC - retailer which owns B&Q and Castorama - Instructs Goldman Sachs International to start the second tranche of the share buy back programme. This will start Wednesday and end no later than June 14. The maximum amount allocated to the tranche will be no greater than GBP50 million. Forms part of overall GBP300 million buy back.

----------

Solid State PLC - Redditch, England-based supplier & design-in manufacturer of computing, power, and communications products - Issues trading update to year ending March 31. Reports a record year with a strong trading performance towards the end of the year. Revenue and adjusted pretax profit are expected to be ahead of consensus expectations. This reflects the recognition of Systems revenue on deliveries in the current financial year. This had previously been expected to be recognised in the financial year to March 2025.

----------

Leeds Group PLC - West Yorkshire, England-based textile manufacturing company - Completes sale of Hemmers-Itex Textil Import Export GmbH. Explains the disposal is deemed to be a sale that divests the company of all, or substantially all of its trading businesses. Therefore, with effect from Tuesday, Leeds is regarded as an AIM Rule 15 cash shell.

----------

LPA Group PLC - Essex-based LED lighting and electro-mechanical systems maker - Issues trading statement at Wednesday's annual general meeting. States first quarter trading has been as anticipated. "Sales levels were largely on target, good order books remain and we are seeing an increased level of activity particularly." Cautions the second quarter "will be affected by late cable shipments which are now coming around the Cape but this will be made up in our third quarter." LPA says "it is clear that the return to profitability will be in our FY25 as some of the growth and profit we were planning for FY24 will have been deferred a further year."

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
26 Sep 2016 14:24

Allergy Therapeutics swings to FY loss on R&D spend

(ShareCast News) - Allergy Therapeutics posted a rise in revenue for the year to the end of June but said it swung to a loss as it ramped up its spending on research and development. Revenue rose 12% from 2015 to £48.5m but the company reported a pre-tax loss of £12.1m versus a profit of £654,000 th

Read more
26 Sep 2016 09:46

Numis reiterates 'buy' on Allergy Therapeutics after full year results

(ShareCast News) - Numis reiterated a 'buy' rating and target price of 37p on Allergy Therapeutics on Monday after the company reported its full year results. Allergy reported a 19% increase in revenue at constant currency to £51.5m in the year ended 30 June as it grew market share in its main Europ

Read more
13 Jul 2016 08:43

Allergy Therapeutics Expects Revenue Rise Despite Euro Weakening

Read more
8 Jul 2016 14:02

Allergy Therapeutics sees good results from Acarovac Plus

(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics published a one-year follow up study of patients using Acarovac Plus on Friday, in the peer-review journal Immunotherapy. The AIM-traded firm's Acarovac Plus product was described as a microcrystalline tyrosine-adsorbed, house

Read more
8 Jul 2016 07:26

Allergy Therapeutics Welcomes Positive Follow-Up Results For Acarovac

Read more
27 Jun 2016 09:51

WINNERS & LOSERS SUMMARY: easyJet And Foxtons In Post-Brexit Warnings

Read more
27 Jun 2016 09:06

Allergy Therapeutics Sees Delayed US Market Launch For GrassMATAMPL

Read more
10 Jun 2016 07:41

Allergy Therapeutics Appoints Skyepharma's Wykeman As Finance Director

Read more
9 May 2016 06:57

Allergy Therapeutics Gets Positive Birch Pollen Treatment Results

Read more
5 Apr 2016 08:12

NetScientic Poaches New Finance Boss From Allergy Therapeutics

Read more
17 Mar 2016 09:08

Allergy Therapeutics Finance Director Ian Postlethwaite Resigns

Read more
10 Mar 2016 09:33

BROKER RATINGS SUMMARY: Jefferies Starts Metro Bank With Buy Rating

Read more
8 Mar 2016 10:59

Allergy Therapeutics Profit Drops On Higher Costs As Revenue Edges Up

Read more
18 Feb 2016 08:08

Allergy Therapeutics Completes Enrolment For Grass Pollen Drug Study

Read more
13 Jan 2016 09:38

Allergy Therapeutics Revenue Up In First Half, Full Year Seen In Line

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.